The role of a novel antiretroviral class (fusion inhibitors) in the management of advanced HIV infection. Preliminary experience with enfuvirtide;Una nuova classe di farmaci antiretrovirali (gli inibitori di fusione) nel trattamento dell'infezione da HIV in fase avanzata. Esperienza preliminare con enfuvirtide

Recenti Progressi in Medicina

Volumn 96, Issue 3, 2005, Pages 124-130

  Manfredi, Roberto ^a   Calza, Leonardo ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral therapy; Enfuvirtide; Fusion inhibitors; Multiresistant HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MALE; MULTIDRUG RESISTANCE; SALVAGE THERAPY;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 22844436084     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Clark RA, Wilcox R, Besch CL. The antiretroviral-experienced patient. Am J Med Sci 2004; 328: 10-6.
2. Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, et al. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their associations with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 2004; 23: 15-22.
3. Rockstroh JK, Mauss S. Clinical perspective of fusion inhibitors for treatment of HIV. J Antimicrob Chemother 2004; 53: 700-2.
4. Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004; 18: 1895-904.
5. Stolk LM, Luers JF. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci 2004; 26: 133-6.
6. Dando TM, Perry CM, Enfuvirtide. Drugs 2003; 63: 2755-66.
7. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 198-211.
8. Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004; 14: 321-37.
9. Hasson H, Castagna A, Clementi M, Menzo S, Denise A, Lazzarin A. The introduction of the fusion inhibitors in the HAART-regimens. New Microbiol 2004; 27 (suppl 1): 11-6.
10. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
11. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New Engl J Med 2003; 348: 2186-95.
12. Crabb C. Clinical trials for enfuvirtide (Fuzeon, T-20). AIDS 2003; 17: N13-4.
13. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA. JAMA 2004; 292: 251-65.
14. McKinney RE Jr, Cunningham CK. Newer treatments for HIV in children. Curr Opin Pediatr 2004; 16: 76-9.
15. Poveda E, Rodes B, Labernardiére JL, Benito JM, Toro C, Gonzalez-Lahoz J, et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004; 74: 21-8.
16. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48: 3253-9.
17. Ferranti S, Menichetti F. Enfuvirtide for prophylaxis against HIV infection. N Engl J Med 2003; 349: 815.
18. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18: 1673-82.
19. Hartt JK, Liang T, Sahagun-Ruiz A, Ming Wang J, Liang-Gao J, Murphy PA. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochem Biophys Res Commun 2000; 272: 699-704.
20. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, et al. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther 2003; 74: 569-80.
21. Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004; 23: 1137-41.
22. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004; 23: 713-8.
23. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 (suppl 2): 61-86.
24. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 53: 678-81.
25. Cohen CJ, Clumeck N, Molina JM, Thompson M, Patel K, Wintfeld N, et al. Health-related quality of life with enfuvirtide (ENF; T.-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004; 37: 1140-6.